Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts

The phosphatidylinositol-3-kinase (PI3K)/Akt signalling pathway is frequently deregulated in pancreatic cancers, and is believed to be an important determinant of their biological aggression and drug resistance. NVP-BEZ235 is a novel, dual class I PI3K/mammalian target of rapamycin (mTor) inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, P, Maira, S-M, García-Echeverría, C, Hedley, D W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/
https://www.ncbi.nlm.nih.gov/pubmed/19319133
http://dx.doi.org/10.1038/sj.bjc.6604995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676548/
https://www.ncbi.nlm.nih.gov/pubmed/19319133
http://dx.doi.org/10.1038/sj.bjc.6604995

Ejemplares similares